Authors
Julio A Ramirez, Frederick J Angulo, Ruth M Carrico, Stephen Furmanek, Senén Peña Oliva, Joann M Zamparo, Elisa Gonzalez, Pingping Zhang, Leslie A Wolf Parrish, Subathra Marimuthu, Michael W Pride, Sharon Gray, Cátia S Matos Ferreira, Forest W Arnold, Raul E Istúriz, Nadia Minarovic, Jennifer C Moïsi, Luis Jodar
Published in
Emerging infectious diseases. Volume 29. Issue 5. Pages 919-928.
Abstract
Although Clostridioides difficile infection (CDI) incidence is high in the United States, standard-of-care (SOC) stool collection and testing practices might result in incidence overestimation or underestimation. We conducted diarrhea surveillance among inpatients >50 years of age in Louisville, Kentucky, USA, during October 14, 2019-October 13, 2020; concurrent SOC stool collection and CDI testing occurred independently. A study CDI case was nucleic acid amplification test‒/cytotoxicity neutralization assay‒positive or nucleic acid amplification test‒positive stool in a patient with pseudomembranous colitis. Study incidence was adjusted for hospitalization share and specimen collection rate and, in a sensitivity analysis, for diarrhea cases without study testing. SOC hospitalized CDI incidence was 121/100,000 population/year; study incidence was 154/100,000 population/year and, in sensitivity analysis, 202/100,000 population/year. Of 75 SOC CDI cases, 12 (16.0%) were not study diagnosed; of 109 study CDI cases, 44 (40.4%) were not SOC diagnosed. CDI incidence estimates based on SOC CDI testing are probably underestimated.
PMID:
37080953
Bibliographic data and abstract were imported from PubMed on 21 Apr 2023.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 57
- Comments 0